Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Artivion (AORT) Short-Term Debt issuances (2020 - 2024)

Artivion posted quarterly Short-Term Debt issuances of -$1.5 million for Q4 2024, down 105.0% on a QoQ basis from $30.0 million in Q1 2024.

Artivion (AORT) has 2 years of Short-Term Debt issuances data on file, last reported at -$1.5 million in Q4 2024.

  • For the quarter ending Q4 2024, Short-Term Debt issuances changed N/A year-over-year to -$1.5 million; the trailing twelve-month figure through Sep 2025 stood at -$1.5 million (down 105.0% YoY), and the FY2024 full-year result was $28.5 million, changed N/A from the prior year.
  • Short-Term Debt issuances for Q4 2024 stood at -$1.5 million, down from $30.0 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $30.0 million in Q1 2020 and bottomed at -$1.5 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 31.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -1.23 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -1.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 37.80 Mn
10 Artivion 1.02 Bn 961.00 Mn 75.45 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -1.50 Mn
Dec 31, 2024 -1.50 Mn
Mar 31, 2024 30.00 Mn
Mar 31, 2024 30.00 Mn
Mar 31, 2020 30.00 Mn
Mar 31, 2020 30.00 Mn